
Rigel earnings beat by $0.12, revenue topped estimates
Investing.com - Rigel (NASDAQ: RIGL) reported second quarter EPS of $0.040, $0.12 better than the analyst estimate of $-0.080. Revenue for the quarter came in at $26.89M versus the consensus...
Investing.com - Rigel (NASDAQ: RIGL) reported second quarter EPS of $0.040, $0.12 better than the analyst estimate of $-0.080. Revenue for the quarter came in at $26.89M versus the consensus...
Rigel (NASDAQ:RIGL) Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral,...
Rigel (NASDAQ:RIGL) Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and positioning of REZLIDHIA®...
Investing.com - Rigel (NASDAQ: RIGL) reported first quarter EPS of $-0.080, $0.02 better than the analyst estimate of $-0.100. Revenue for the quarter came in at $26.1M versus the consensus...
A Piper Sandler analyst initiated new coverage Rigel (NASDAQ: RIGL) Neutral rating and a price target of $2.00. Prior to this rating, Rigel had 2 buy ratings, 3 hold ratings, and 0 sell...
By Oliver Gray Investing.com - U.S. stock futures were little changed on Tuesday, after a negative session among major benchmark averages as investors retreated following Federal Reserve...
After-Hours Movers: Rigel Pharma (NASDAQ:RIGL) 21% HIGHER; {{erl-17057||reported Q4 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $51.3...
Rigel Pharma (NASDAQ:RIGL) reported Q4 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $51.3 million versus the consensus estimate of...
Investing.com - Rigel (NASDAQ: RIGL) reported first quarter EPS of $0.010, $0.10 better than the analyst estimate of $-0.090. Revenue for the quarter came in at $51.3M versus the consensus...
After-Hours Stock Movers: Rigel (NASDAQ:RIGL) Pharmaceuticals, Inc. (Nasdaq: RIGL) 12% LOWER; received guidance from the U.S. Food and Drug Administration (FDA)'s review of the Company's...
Pre-Open Stock Movers:Wolfspeed (WOLF) 21% HIGHER; reported Q4 EPS of ($0.02), $0.08 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $228.5 million versus the...
Rigel Pharma (NASDAQ:RIGL) reported Q2 EPS of ($0.08), $0.04 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $29.8 million versus the consensus estimate of...
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Basic Materials, Utilities and Industrials sectors propelled shares lower. At the close in NYSE, the Dow...
Pre-Open Stock Movers:Rigel (NASDAQ:RIGL) Pharmaceuticals, Inc. (Nasdaq: RIGL) 46% LOWER; announced top-line efficacy and safety data from the FORWARD Phase 3 clinical trial, a global,...
Rigel Pharma (NASDAQ:RIGL) reported Q1 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $16.74 million versus the consensus estimate of...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Industrials, Oil & Gas and Basic Materials sectors propelled shares higher. At the close in NYSE, the...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Oil & Gas, Basic Materials and Industrials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. futures were gaining traction on Thursday as the chances of a Federal Reserve rate hike look more likely. The S&P 500 futures was steady at 0.01% as of 6:27...
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Utilities, Consumer Goods and Oil & Gas sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.